Semaglutide and MASH: the liver disease approval explained

Step 1: understanding what MASH actually is

MASH is the more serious end of a spectrum of liver conditions collectively called MASLD (metabolic dysfunction-associated steatotic liver disease, previously known as NAFLD). Fat accumulates in the liver, that is steatosis. When the liver becomes inflamed on top of that, and the tissue begins to scar, the condition becomes MASH. Left unmanaged, scarring can advance to cirrhosis and liver failure.

The condition is closely linked to obesity, type 2 diabetes and metabolic syndrome, which is one reason a GLP-1 medicine like semaglutide attracted research interest. Weight loss and improved metabolic control reduce the inflammatory burden on the liver, and trial data suggested semaglutide could reduce fibrosis scores in some patients.

There are no dramatic symptoms in early MASH, which makes it easy to miss. Most patients come to it through abnormal liver function blood tests, imaging, or monitoring of a related condition. By the time fibrosis is classified as moderate-to-advanced (the group covered by this approval) specialist input is already part of the picture. For context on how semaglutide interacts with other metabolic conditions, the connection between semaglutide and blood pressure shows how the medicine's metabolic effects can reach beyond a single organ system.

Step 2: what the MHRA approval actually covers

The 3 July 2026 conditional approval was reported by the UK government and confirmed by Novo Nordisk. The indication is specifically for adults with MASH and moderate-to-advanced fibrosis. "Conditional" approval means the MHRA is satisfied with the existing evidence but has required the manufacturer to provide further data as the medicine is used in this population, it does not mean the approval is provisional or likely to be withdrawn.

This is categorically separate from semaglutide's weight-management licence (Wegovy, BMI ≥30 or ≥27 with a weight-related comorbidity) and its type 2 diabetes licence (Ozempic). The MASH approval has its own eligibility criteria, its own clinical endpoints and its own monitoring framework. A patient being treated for MASH with semaglutide is not simply being prescribed a weight-loss drug; they are under specialist hepatological care.

The full background on the approval and what it signals for liver disease treatment is covered in our dedicated piece on Wegovy and MASH, including the clinical trial evidence the MHRA reviewed. For the official source, the government's announcement is available on GOV.UK and is the most precise statement of what was granted and when.

Step 3: how this sits alongside semaglutide's other licensed uses

Semaglutide now holds three distinct UK licences: weight management, reduction of major cardiovascular event risk in eligible adults, and MASH treatment for patients with moderate-to-advanced fibrosis. These share a molecule and a delivery mechanism but differ in their patient populations, eligibility criteria and the clinical teams involved.

A question our prescribers hear most weeks, since the MASH approval was announced, is whether someone with fatty liver disease could use a weight-management prescription to address their liver condition. The honest answer is no, not through the weight-management pathway. MASH treatment requires specialist assessment of liver fibrosis staging, which is not part of a weight-management consultation. The routes are separate, and rightly so.

That said, the overlap between the two populations is real. Many people who would qualify for weight-management treatment with semaglutide also have liver disease related to their weight. In those cases, it is worth discussing the full clinical picture with a specialist who can assess whether the weight-management and liver-disease pathways should be considered together. Our full semaglutide guide sets out what the weight-management licence covers and how the prescription process works for that indication specifically.

Step 4: what people considering semaglutide for weight management should know about this approval

If you are looking at semaglutide for weight management (rather than for MASH specifically) the 3 July 2026 approval does not change the eligibility criteria or the prescription process for Wegovy. The weight-management licence remains its own route: BMI threshold, clinical assessment, prescriber review, and an ongoing monitoring relationship.

What the MASH approval does add is a clearer picture of semaglutide's broader metabolic effects. The liver benefits observed in the trial population reflect mechanisms that are already part of how the medicine works: reduced appetite, lower body weight, improved insulin sensitivity, and reduced inflammation. Those effects are relevant context, though not a clinical claim about what any individual patient will experience.

For a realistic sense of what Wegovy costs through a private regulated pharmacy, the Wegovy price comparison guide sets out what to expect. The detailed breakdown of the semaglutide MASH approval timeline is the right place if you want the regulatory steps explained more fully. And if your interest is in the weight-management route rather than liver disease treatment, the NHS medicines information on semaglutide (available at NHS.uk) is a well-maintained patient-facing resource that covers the weight-management licence accurately.